BioAge Labs, a clinical-stage biotech developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ.
BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest.
Longevity. Technology: Muscle atrophy – loss of muscle mass and strength – is a universal feature of human aging that increases the risk of multiple morbidities, shortens lifespan and diminishes quality of life. Hospitalisation and periods of forced inactivity greatly accelerate this loss in older people.
Comments are closed.